Company: CERO
Filing Date: 2025-05-27
Form Type: POS AM
Source: 0001213900-25-047469
Chunk: 246

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-27
Form: POS AM
Chunk 246
---
    Underlying 
   Unexercised 
   Options (#) 
   Exercisable |     |     Number of 
    Securities 
    Underlying 
   Unexercised 
   Options (#) 
 Unexercisable |     |   |   Option 
 Exercise 
    Price 
      ($) |     | Option     
 Expiration 
 Date       |
|:-------------------------------|:----|:-----------|:----|:-------------|:----|--------------:|:----|--------------:|:----|:--|---------:|:----|:-----------|
| Chris Ehrlich,                 
 Chief Executive Officer        |     | 10/01/2024 |     | 12/02/2024   |     |        25,550 |     |             — |     | $ |    10.00 |     | 09/30/2034 |
| Brian G. Atwood,               
 Former Chief Executive Officer |     | 10/01/2024 |     | 12/02/2024   |     |         5,080 |     |             — |     | $ |    10.00 |     | 09/30/2034 |
| Andrew “Al” Kucharchuk,        
 Chief Financial Officer        |     | 10/01/2024 |     | 10/01/2024   |     |         1,250 |     |         3,750 |     | $ |    10.00 |     | 09/30/2034 |
| Kristen Pierce, Ph.D.          
 Chief Development Officer      |     | 10/01/2024 |     | 10/01/2024   |     |         1,784 |     |           875 |     | $ |    10.00 |     | 09/30/2034 |

Employee Benefits and Equity Incentive Compensation Plan Equity Incentive Compensation We believe it is important to maintain a strong link between executive incentives and the creation of stockholder value. We believe performance and equity-based compensation for our executives to be an important component of maximizing stockholder value while, at the same time, attracting, motivating and retaining high-quality executives. Upon consummation of the Business Combination, we assumed options issued pursuant to the CERo Therapeutics, Inc. 2016 Equity Incentive Plan, as amended (the “2016 Plan”), and we currently maintain the CER